LSPN Europe: new challenges for drug patent owners in Russia

21-11-2019

Rory O'Neill

LSPN Europe: new challenges for drug patent owners in Russia

Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.


LSPN 19, Hogan Lovells, Natalia Gulyaeva, Novartis, MA, market authorisation, compulsory licensing

LSIPR